Hefei Life Science to Develop Micell Technologies' Stent in China
10/3/2013 10:18:56 AM
by Richard Daverman, PhD
October 3, 2013 -- Hefei Life Science will fund the China clinical development of a drug eluting stent produced by Micell Technologies, a North Carolina interventional cardiology device maker. Once the stent is approved by the CFDA, Micell will continue to manufacture the MiStent SES. Sinopharm will be responsible for distribution, and SinoMedCare of Shanghai will contribute marketing and sales support. The agreement includes annual purchase commitments after the product is approved for sale. Hefei Life Science was established to bring high-tech bio-pharmaceutical projects with good market prospects to Hefei Life Science Park. More details....
Help employers find you! Check out all the jobs and post your resume.
comments powered by